soul trial oral semaglutide cardiovascular outcomes PDF) Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized SOUL trial: Oral semaglutide demonstrates
Description
Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans
Clinical trial data (Jastreboff et al., NEJM 2023
placebo for a 48-week period
Then GLP-1 medications hit the market
Research on GLP-1 therapy shows that consistent weekly injections drive steady results
